IDXX IDEXX Laboratories Inc
Company Analysis
Latest News
IDEXX Beats on Every Line and Raises Its Outlook — But Can an 18% Pop Survive a Margin Squeeze?
Shares of IDEXX Laboratories surged 18.1% to $650.87 Monday morning after the veterinary diagnostics giant delivered a Q3 earnings report that cleared Wall...
🟢 IDEXX is trading 18% up today after beating Q3 estimates and raising 2026 guidance
IDEXX is trading at $650.87, up 18.08%, after beating Q3 estimates and raising its 2026 outlook. - Third-quarter revenue was $1.21 billion and adjusted EPS...
🟢 IDEXX is trading 4.3% up in pre-market after Q3 beat and 2026 guidance hike
IDEXX is trading $574.70 (+4.26%) in pre-market on November 2 after third-quarter results beat analyst expectations. - Revenue was $1.21 billion and reported...
IDEXX Laboratories third quarter results beat expectations behind 11% organic CAG diagnostics growth
IDEXX reported a strong third quarter with revenue and earnings exceeding analyst estimates, driven by double-digit organic growth in its core veterinary...
IDEXX Laboratories Inc Q3 2026 Earnings Preview: What Analysts Expect on November 02, 2026
IDEXX Laboratories is expected to report Q3 2026 revenue of $1.19 billion and EPS of $3.71, with its current stock price of $575.98 trading well below the...
🔴 IDEXX is trading 5.75% down with no clear company-specific catalyst
IDEXX is trading 5.75% down at $548.94 on October 30, 2026, with no clear company-specific announcement identified to explain the decline. - UBS cut its price...
🔴 IDEXX is trading 9% down in pre-market with no clear company-specific catalyst identified
IDEXX is trading 9.22% down at $510.99 in pre-market on October 29, with no clear company-specific announcement explaining the move. - IDEXX is scheduled to...
🟢 IDEXX is trading 4.14% up in pre-market with no confirmed catalyst for the rise
IDEXX is trading 4.14% higher at $539.43 before the October 12, 2026 session, with no confirmed new company announcement explaining the pre-market move. - The...
🟢 IDEXX is trading 4.7% up in pre-market with no clear catalyst identified
IDEXX is trading 4.67% up at $539.48 before the October 7, 2026 session; no clear company-specific catalyst has been identified. - An October 7 article...
🟢 IDEXX is trading 4.1% up in pre-market with no verified company-specific catalyst
IDEXX is trading at $539.01, +4.11% versus the October 1 close, with no clearly verified company-specific announcement on October 2 explaining the pre-market...
🔴 IDEXX is trading 4.21% down in pre-market — catalyst remains unclear
IDEXX is trading 4.21% down at $511.00 in pre-market on September 30, 2026, with the immediate catalyst unclear. - The price compares with IDEXX’s September...
🟢 IDEXX is trading 13.3% up in pre-market amid broader market and growth-stock strength
IDEXX is trading at $584.05, up 13.34%, amid broader market and growth-stock strength. - No new company-specific announcement for September 22, 2026 was...
IDEXX Acquires CoVetAI, Automating Veterinary Documentation With AI
IDEXX Laboratories acquired CoVetAI Inc., a developer of AI-native ambient listening and clinical workflow software for veterinary practices. Financial terms...
🟢 IDEXX is trading 5.7% up in pre-market after August inflation data
IDEXX is trading 5.68% up at $535.33 after a broad market relief rally following August inflation data. - The S&P 500, Nasdaq Composite, and Dow Jones were...
Baillie Gifford Initiates New $186M Position in Idexx Laboratories (IDXX)
Baillie Gifford, a prominent global investment manager, has established a new stake in Idexx Laboratories, a leader in veterinary diagnostics and software....
Jensen Investment Management boosts IDEXX stake by over 2800%
Jensen Investment Management significantly increased its investment in veterinary diagnostics leader IDEXX Laboratories (IDXX), according to a recent quarterly...
Terry Smith's Fundsmith Trims IDEXX Labs Stake by Over 30%
In a notable portfolio adjustment, Terry Smith's Fundsmith reduced its holding in IDEXX Laboratories by 30.42%, selling an estimated $234.74 million worth of...
IDEXX Laboratories' second quarter revenue and EPS beat estimates, driven by 10% organic growth in its key diagnostics business.
IDEXX Laboratories reported second quarter 2026 revenue of $1.217 billion, up 10% year-over-year, and EPS of $4.27, an 18% increase. Both top and bottom-line...
IDEXX Laboratories Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Wall Street expects IDEXX Laboratories to report Q2 2026 revenue of $1.20 billion and earnings per share of $3.95, while the stock currently trades around...
IDEXX Laboratories beats first quarter 2026 estimates with 11% organic growth in CAG diagnostics and raises full-year guidance.
IDEXX Laboratories reported first quarter 2026 revenue of $1.141 billion, up 14% as reported and 11% on an organic basis, beating estimates. Earnings per share...